WO2012051741A1 - 抑制黑色素生成的甘胺酸衍生物及其美白组合物 - Google Patents
抑制黑色素生成的甘胺酸衍生物及其美白组合物 Download PDFInfo
- Publication number
- WO2012051741A1 WO2012051741A1 PCT/CN2010/001665 CN2010001665W WO2012051741A1 WO 2012051741 A1 WO2012051741 A1 WO 2012051741A1 CN 2010001665 W CN2010001665 W CN 2010001665W WO 2012051741 A1 WO2012051741 A1 WO 2012051741A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- acid
- glycine
- weight
- glycine derivative
- acetylamino
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 48
- 230000002087 whitening effect Effects 0.000 title claims abstract description 43
- 230000008099 melanin synthesis Effects 0.000 title claims abstract description 23
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical class NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 title claims abstract description 20
- 230000002401 inhibitory effect Effects 0.000 title claims abstract description 19
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims abstract description 4
- 150000002332 glycine derivatives Chemical class 0.000 claims description 39
- -1 2-Acetylamino-acetyl Chemical group 0.000 claims description 18
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 12
- 239000002253 acid Substances 0.000 claims description 11
- 239000007853 buffer solution Substances 0.000 claims description 10
- 239000004471 Glycine Substances 0.000 claims description 9
- 239000007864 aqueous solution Substances 0.000 claims description 8
- 238000002834 transmittance Methods 0.000 claims description 7
- 239000000126 substance Substances 0.000 claims description 5
- DVFCNLLHWZAEQR-UHFFFAOYSA-N 2-[(2-acetamidoacetyl)-methylamino]acetic acid Chemical group OC(=O)CN(C)C(=O)CNC(C)=O DVFCNLLHWZAEQR-UHFFFAOYSA-N 0.000 claims description 3
- 125000000217 alkyl group Chemical group 0.000 claims description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 3
- 150000003839 salts Chemical class 0.000 claims description 3
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 claims 2
- XEYXABYHOZPZRT-UHFFFAOYSA-N C(C)(=O)NCC(=O)NCCC(=O)O.C(C)(=O)NCC(=O)NC(C(=O)O)C Chemical compound C(C)(=O)NCC(=O)NCCC(=O)O.C(C)(=O)NCC(=O)NC(C(=O)O)C XEYXABYHOZPZRT-UHFFFAOYSA-N 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 abstract description 37
- 230000000694 effects Effects 0.000 abstract description 13
- 239000002537 cosmetic Substances 0.000 abstract description 4
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 1
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 34
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 24
- 238000009472 formulation Methods 0.000 description 22
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 20
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 17
- 108010016626 Dipeptides Proteins 0.000 description 15
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 15
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 13
- 210000003491 skin Anatomy 0.000 description 13
- 238000012360 testing method Methods 0.000 description 13
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 12
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 12
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- 239000004480 active ingredient Substances 0.000 description 12
- 235000010323 ascorbic acid Nutrition 0.000 description 12
- 239000011668 ascorbic acid Substances 0.000 description 12
- 229960004441 tyrosine Drugs 0.000 description 12
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 12
- 235000002374 tyrosine Nutrition 0.000 description 12
- 229960005070 ascorbic acid Drugs 0.000 description 11
- 230000005764 inhibitory process Effects 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- 102000003425 Tyrosinase Human genes 0.000 description 9
- 108060008724 Tyrosinase Proteins 0.000 description 9
- 238000000034 method Methods 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 125000003118 aryl group Chemical group 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 8
- 239000000523 sample Substances 0.000 description 8
- 239000002689 soil Substances 0.000 description 8
- BEJNERDRQOWKJM-UHFFFAOYSA-N kojic acid Chemical compound OCC1=CC(=O)C(O)=CO1 BEJNERDRQOWKJM-UHFFFAOYSA-N 0.000 description 7
- 229960004705 kojic acid Drugs 0.000 description 7
- WZNJWVWKTVETCG-UHFFFAOYSA-N kojic acid Natural products OC(=O)C(N)CN1C=CC(=O)C(O)=C1 WZNJWVWKTVETCG-UHFFFAOYSA-N 0.000 description 7
- 230000003287 optical effect Effects 0.000 description 7
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 7
- OKJIRPAQVSHGFK-UHFFFAOYSA-N N-acetylglycine Chemical compound CC(=O)NCC(O)=O OKJIRPAQVSHGFK-UHFFFAOYSA-N 0.000 description 6
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 6
- 239000003054 catalyst Substances 0.000 description 6
- 235000011187 glycerol Nutrition 0.000 description 6
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 6
- BJRNKVDFDLYUGJ-RMPHRYRLSA-N hydroquinone O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-RMPHRYRLSA-N 0.000 description 6
- 239000006210 lotion Substances 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 238000002835 absorbance Methods 0.000 description 5
- 239000012091 fetal bovine serum Substances 0.000 description 5
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 5
- SCVZUBLUQMMQED-UHFFFAOYSA-N 2-[(2-acetamidoacetyl)amino]propanoic acid Chemical compound OC(=O)C(C)NC(=O)CNC(C)=O SCVZUBLUQMMQED-UHFFFAOYSA-N 0.000 description 4
- 102000030523 Catechol oxidase Human genes 0.000 description 4
- 108010031396 Catechol oxidase Proteins 0.000 description 4
- 229920001213 Polysorbate 20 Polymers 0.000 description 4
- 229960000271 arbutin Drugs 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 239000011259 mixed solution Substances 0.000 description 4
- 230000003647 oxidation Effects 0.000 description 4
- 238000007254 oxidation reaction Methods 0.000 description 4
- 230000001590 oxidative effect Effects 0.000 description 4
- 230000001766 physiological effect Effects 0.000 description 4
- 229920000193 polymethacrylate Polymers 0.000 description 4
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 4
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 4
- 229940068977 polysorbate 20 Drugs 0.000 description 4
- 239000012488 sample solution Substances 0.000 description 4
- 150000003700 vitamin C derivatives Chemical class 0.000 description 4
- YHHHHJCAVQSFMJ-FNORWQNLSA-N (3e)-deca-1,3-diene Chemical compound CCCCCC\C=C\C=C YHHHHJCAVQSFMJ-FNORWQNLSA-N 0.000 description 3
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 3
- DMDZEFFXNSRFRC-UHFFFAOYSA-N 4-[(2-acetamidoacetyl)amino]butanoic acid Chemical group CC(=O)NCC(=O)NCCCC(O)=O DMDZEFFXNSRFRC-UHFFFAOYSA-N 0.000 description 3
- QCZAWDGAVJMPTA-RNFRBKRXSA-N ClC1=CC=CC(=N1)C1=NC(=NC(=N1)N[C@@H](C(F)(F)F)C)N[C@@H](C(F)(F)F)C Chemical compound ClC1=CC=CC(=N1)C1=NC(=NC(=N1)N[C@@H](C(F)(F)F)C)N[C@@H](C(F)(F)F)C QCZAWDGAVJMPTA-RNFRBKRXSA-N 0.000 description 3
- AHMIDUVKSGCHAU-UHFFFAOYSA-N Dopaquinone Natural products OC(=O)C(N)CC1=CC(=O)C(=O)C=C1 AHMIDUVKSGCHAU-UHFFFAOYSA-N 0.000 description 3
- 229920001503 Glucan Polymers 0.000 description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 3
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 3
- MLSJBGYKDYSOAE-DCWMUDTNSA-N L-Ascorbic acid-2-glucoside Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)=C1O MLSJBGYKDYSOAE-DCWMUDTNSA-N 0.000 description 3
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 3
- AHMIDUVKSGCHAU-LURJTMIESA-N L-dopaquinone Chemical compound [O-]C(=O)[C@@H]([NH3+])CC1=CC(=O)C(=O)C=C1 AHMIDUVKSGCHAU-LURJTMIESA-N 0.000 description 3
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- YPHXELXTJORXAT-UHFFFAOYSA-N NCCCC(O)=O.CC(=O)NCC(O)=O Chemical compound NCCCC(O)=O.CC(=O)NCC(O)=O YPHXELXTJORXAT-UHFFFAOYSA-N 0.000 description 3
- 238000005481 NMR spectroscopy Methods 0.000 description 3
- 239000004721 Polyphenylene oxide Substances 0.000 description 3
- 229920002385 Sodium hyaluronate Polymers 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 150000001413 amino acids Chemical group 0.000 description 3
- 229960000541 cetyl alcohol Drugs 0.000 description 3
- 229920006037 cross link polymer Polymers 0.000 description 3
- 230000003013 cytotoxicity Effects 0.000 description 3
- 231100000135 cytotoxicity Toxicity 0.000 description 3
- 229940075529 glyceryl stearate Drugs 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 3
- 239000012535 impurity Substances 0.000 description 3
- 239000011777 magnesium Substances 0.000 description 3
- 229910052749 magnesium Inorganic materials 0.000 description 3
- 230000003061 melanogenesis Effects 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 3
- BJRNKVDFDLYUGJ-UHFFFAOYSA-N p-hydroxyphenyl beta-D-alloside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-UHFFFAOYSA-N 0.000 description 3
- 229920000570 polyether Polymers 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 229940010747 sodium hyaluronate Drugs 0.000 description 3
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 3
- 238000001228 spectrum Methods 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 125000003396 thiol group Chemical group [H]S* 0.000 description 3
- HBXWUCXDUUJDRB-UHFFFAOYSA-N 1-octadecoxyoctadecane Chemical compound CCCCCCCCCCCCCCCCCCOCCCCCCCCCCCCCCCCCC HBXWUCXDUUJDRB-UHFFFAOYSA-N 0.000 description 2
- SXHVOQKAFHFDJM-UHFFFAOYSA-N 2-acetamidoacetic acid;2-(methylamino)acetic acid Chemical compound CNCC(O)=O.CC(=O)NCC(O)=O SXHVOQKAFHFDJM-UHFFFAOYSA-N 0.000 description 2
- DHHJFHDJJLVACS-UHFFFAOYSA-N 2-acetamidoacetic acid;3-aminopropanoic acid Chemical compound NCCC(O)=O.CC(=O)NCC(O)=O DHHJFHDJJLVACS-UHFFFAOYSA-N 0.000 description 2
- CDAWCLOXVUBKRW-UHFFFAOYSA-N 2-aminophenol Chemical compound NC1=CC=CC=C1O CDAWCLOXVUBKRW-UHFFFAOYSA-N 0.000 description 2
- 229940100555 2-methyl-4-isothiazolin-3-one Drugs 0.000 description 2
- YOETUEMZNOLGDB-UHFFFAOYSA-N 2-methylpropyl carbonochloridate Chemical compound CC(C)COC(Cl)=O YOETUEMZNOLGDB-UHFFFAOYSA-N 0.000 description 2
- QRYRORQUOLYVBU-VBKZILBWSA-N Carnosic acid Natural products CC([C@@H]1CC2)(C)CCC[C@]1(C(O)=O)C1=C2C=C(C(C)C)C(O)=C1O QRYRORQUOLYVBU-VBKZILBWSA-N 0.000 description 2
- 108010087806 Carnosine Proteins 0.000 description 2
- 240000005250 Chrysanthemum indicum Species 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 244000042664 Matricaria chamomilla Species 0.000 description 2
- 235000007232 Matricaria chamomilla Nutrition 0.000 description 2
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 2
- CQOVPNPJLQNMDC-UHFFFAOYSA-N N-beta-alanyl-L-histidine Natural products NCCC(=O)NC(C(O)=O)CC1=CN=CN1 CQOVPNPJLQNMDC-UHFFFAOYSA-N 0.000 description 2
- 102000004316 Oxidoreductases Human genes 0.000 description 2
- 108090000854 Oxidoreductases Proteins 0.000 description 2
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 150000008065 acid anhydrides Chemical class 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 229940044199 carnosine Drugs 0.000 description 2
- CQOVPNPJLQNMDC-ZETCQYMHSA-N carnosine Chemical compound [NH3+]CCC(=O)N[C@H](C([O-])=O)CC1=CNC=N1 CQOVPNPJLQNMDC-ZETCQYMHSA-N 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 230000006866 deterioration Effects 0.000 description 2
- MIMDHDXOBDPUQW-UHFFFAOYSA-N dioctyl decanedioate Chemical compound CCCCCCCCOC(=O)CCCCCCCCC(=O)OCCCCCCCC MIMDHDXOBDPUQW-UHFFFAOYSA-N 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 229930182478 glucoside Natural products 0.000 description 2
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- UKVIEHSSVKSQBA-UHFFFAOYSA-N methane;palladium Chemical compound C.[Pd] UKVIEHSSVKSQBA-UHFFFAOYSA-N 0.000 description 2
- BEGLCMHJXHIJLR-UHFFFAOYSA-N methylisothiazolinone Chemical compound CN1SC=CC1=O BEGLCMHJXHIJLR-UHFFFAOYSA-N 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 239000013074 reference sample Substances 0.000 description 2
- 230000003716 rejuvenation Effects 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 239000012085 test solution Substances 0.000 description 2
- 238000001291 vacuum drying Methods 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- ADFXKUOMJKEIND-UHFFFAOYSA-N 1,3-dicyclohexylurea Chemical compound C1CCCCC1NC(=O)NC1CCCCC1 ADFXKUOMJKEIND-UHFFFAOYSA-N 0.000 description 1
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
- NLMKTBGFQGKQEV-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-(2-hexadecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO NLMKTBGFQGKQEV-UHFFFAOYSA-N 0.000 description 1
- AIOCLJDAYKBSTO-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[4-(2,4,4-trimethylpentan-2-yl)phenoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CC(C)(C)CC(C)(C)C1=CC=C(OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)C=C1 AIOCLJDAYKBSTO-UHFFFAOYSA-N 0.000 description 1
- LCVHZNSIAYNAGX-UHFFFAOYSA-N 2-ethylhexyl 3,5,5-trimethylhexanoate Chemical compound CCCCC(CC)COC(=O)CC(C)CC(C)(C)C LCVHZNSIAYNAGX-UHFFFAOYSA-N 0.000 description 1
- ICIDSZQHPUZUHC-UHFFFAOYSA-N 2-octadecoxyethanol Chemical compound CCCCCCCCCCCCCCCCCCOCCO ICIDSZQHPUZUHC-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 241000283153 Cetacea Species 0.000 description 1
- 235000007516 Chrysanthemum Nutrition 0.000 description 1
- 235000018959 Chrysanthemum indicum Nutrition 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 206010012442 Dermatitis contact Diseases 0.000 description 1
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-N Formic acid Chemical compound OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101001061788 Homo sapiens Ras-related protein Rab-35 Proteins 0.000 description 1
- MIJPAVRNWPDMOR-ZAFYKAAXSA-N L-ascorbic acid 2-phosphate Chemical compound OC[C@H](O)[C@H]1OC(=O)C(OP(O)(O)=O)=C1O MIJPAVRNWPDMOR-ZAFYKAAXSA-N 0.000 description 1
- 241000801118 Lepidium Species 0.000 description 1
- 240000000759 Lepidium meyenii Species 0.000 description 1
- 235000000421 Lepidium meyenii Nutrition 0.000 description 1
- 231100000002 MTT assay Toxicity 0.000 description 1
- 238000000134 MTT assay Methods 0.000 description 1
- 241000208467 Macadamia Species 0.000 description 1
- 235000018330 Macadamia integrifolia Nutrition 0.000 description 1
- 235000019493 Macadamia oil Nutrition 0.000 description 1
- 240000000912 Macadamia tetraphylla Species 0.000 description 1
- 235000003800 Macadamia tetraphylla Nutrition 0.000 description 1
- 235000017945 Matricaria Nutrition 0.000 description 1
- 108010007013 Melanocyte-Stimulating Hormones Proteins 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 102000008109 Mixed Function Oxygenases Human genes 0.000 description 1
- 108010074633 Mixed Function Oxygenases Proteins 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Substances CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 1
- 102100029568 Ras-related protein Rab-35 Human genes 0.000 description 1
- KJTLSVCANCCWHF-UHFFFAOYSA-N Ruthenium Chemical compound [Ru] KJTLSVCANCCWHF-UHFFFAOYSA-N 0.000 description 1
- 241001558929 Sclerotium <basidiomycota> Species 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- UCKMPCXJQFINFW-UHFFFAOYSA-N Sulphide Chemical compound [S-2] UCKMPCXJQFINFW-UHFFFAOYSA-N 0.000 description 1
- 101710147108 Tyrosinase inhibitor Proteins 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- PYKYMHQGRFAEBM-UHFFFAOYSA-N anthraquinone Natural products CCC(=O)c1c(O)c2C(=O)C3C(C=CC=C3O)C(=O)c2cc1CC(=O)OC PYKYMHQGRFAEBM-UHFFFAOYSA-N 0.000 description 1
- 150000004056 anthraquinones Chemical class 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- ZKIFKIPAGDGRFG-UHFFFAOYSA-N benzyl 2-(methylamino)acetate Chemical compound CNCC(=O)OCC1=CC=CC=C1 ZKIFKIPAGDGRFG-UHFFFAOYSA-N 0.000 description 1
- CANCPUBPPUIWPX-UHFFFAOYSA-N benzyl 3-aminopropanoate Chemical compound NCCC(=O)OCC1=CC=CC=C1 CANCPUBPPUIWPX-UHFFFAOYSA-N 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 229960001631 carbomer Drugs 0.000 description 1
- 230000006315 carbonylation Effects 0.000 description 1
- 238000005810 carbonylation reaction Methods 0.000 description 1
- 229940056318 ceteth-20 Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 208000010247 contact dermatitis Diseases 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 208000030381 cutaneous melanoma Diseases 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 1
- 150000002009 diols Chemical class 0.000 description 1
- CZZYITDELCSZES-UHFFFAOYSA-N diphenylmethane Chemical group C=1C=CC=CC=1CC1=CC=CC=C1 CZZYITDELCSZES-UHFFFAOYSA-N 0.000 description 1
- 238000002845 discoloration Methods 0.000 description 1
- VJNCICVKUHKIIV-UHFFFAOYSA-N dopachrome Chemical compound O=C1C(=O)C=C2NC(C(=O)O)CC2=C1 VJNCICVKUHKIIV-UHFFFAOYSA-N 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 210000001339 epidermal cell Anatomy 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 229940100549 ethylhexyl isononanoate Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- MGIYRDNGCNKGJU-UHFFFAOYSA-N isothiazolinone Chemical compound O=C1C=CSN1 MGIYRDNGCNKGJU-UHFFFAOYSA-N 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 235000012902 lepidium meyenii Nutrition 0.000 description 1
- 239000010469 macadamia oil Substances 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 210000002752 melanocyte Anatomy 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- NCPHGZWGGANCAY-UHFFFAOYSA-N methane;ruthenium Chemical compound C.[Ru] NCPHGZWGGANCAY-UHFFFAOYSA-N 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 125000001421 myristyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229940078812 myristyl myristate Drugs 0.000 description 1
- 231100000065 noncytotoxic Toxicity 0.000 description 1
- 230000002020 noncytotoxic effect Effects 0.000 description 1
- IMKAZTAYLVONBX-UHFFFAOYSA-N octan-3-yl hexanoate Chemical compound CCCCCC(CC)OC(=O)CCCCC IMKAZTAYLVONBX-UHFFFAOYSA-N 0.000 description 1
- 229920004906 octoxynol-11 Polymers 0.000 description 1
- 150000002923 oximes Chemical group 0.000 description 1
- 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 229910052707 ruthenium Inorganic materials 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 201000003708 skin melanoma Diseases 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 229940100459 steareth-20 Drugs 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- DZKXJUASMGQEMA-UHFFFAOYSA-N tetradecyl tetradecanoate Chemical compound CCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCC DZKXJUASMGQEMA-UHFFFAOYSA-N 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- WHNFPRLDDSXQCL-UHFFFAOYSA-N α-melanotropin Chemical compound C=1N=CNC=1CC(C(=O)NC(CC=1C=CC=CC=1)C(=O)NC(CCCNC(N)=N)C(=O)NC(CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)NC(CCCCN)C(=O)N1C(CCC1)C(=O)NC(C(C)C)C(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(CCSC)NC(=O)C(CO)NC(=O)C(NC(=O)C(CO)NC(C)=O)CC1=CC=C(O)C=C1 WHNFPRLDDSXQCL-UHFFFAOYSA-N 0.000 description 1
- SFVVQRJOGUKCEG-OPQSFPLASA-N β-MSH Chemical compound C1C[C@@H](O)[C@H]2C(COC(=O)[C@@](O)([C@@H](C)O)C(C)C)=CCN21 SFVVQRJOGUKCEG-OPQSFPLASA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/45—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
- C07C233/46—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
- C07C233/47—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
- C07C237/22—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
Definitions
- the present invention relates to a glycine derivative, and more particularly to a whitening composition having a glycine-staining organism which inhibits the production of melanin and a whitening composition using the same.
- tyrosinase The mechanism of the formation of melanin (melanin) is thought to be related to tyrosinase.
- tyrosine the precursor of melanin
- aminic acid ⁇ Dopa ⁇ Dopaquinone "Dopachrome" - melanin
- tyrosinase is an important enzyme, which converts tyrosine to dopa by the activity of its hydroxylase, and converts dopa to dopaquinone by the activity of oxidase.
- melanogenesis substances that inhibit melanogenesis (mel anogenes is), or inhibit any process of melanin biosynthesis, can be used as an active ingredient in skin whitening.
- the first step in melanin production initiation is by tyrosine
- the enzyme catalyzes the oxidation of tyrosine to form dopaquinone.
- tyrosinase inhibitor is one of the active ingredients for skin whitening.
- whitening main components such as Kojic acid (Kojic ac id), vitamin C derivatives (ascorbic acid derivat ives), and arbutin, are known to have the function of inhibiting tyrosinase activity. Compound.
- the kojic acid is unstable in solution, resulting in a complicated procedure for formulation (refer to the description of US Pat. No. 6,306, 376), and it can cause skin irritation when applied to skin care products (refer to Contact Dermatitis, Jan 95, Vol. 42 (1) , Page 9 ⁇ 13) , all of which limit the usefulness of their whitening formula.
- Vitamin C is very unstable and highly susceptible to oxidative deterioration. Therefore, vitamin C derivatives are often used in whitening formulations to enhance the stability of the formulation. However, it is still necessary to add a stabilizer such as sod iuin hydrogen sulfate in the formulation or to prepare a buffer solution to reduce the degree of oxidative discoloration of the formulation. (Refer to the examples of U.S. Patent No. 6,801,050) However, the use of sulfide as a stabilizer is likely to cause a pungent odor in the product (refer to the description of US 6,020,367), so the method is not simultaneously Solve the requirements and problems of color and odor for whitening formulas.
- a stabilizer such as sod iuin hydrogen sulfate
- arbutin has a whitening effect
- its structure is a glycated derivative of hydroquinone (Glycosylated hydroquinone), which is still easily discolored by the oxidation of aromatic phenolic groups in the formulation, which makes the formulation difficult.
- the low solubility of arbutin in water results in a low whitening effect actually produced by the application of the concentration H in the formulation (refer to Japanese Patent Laid-Open Publication No. 2009-67691), Japanese Patent Laid-Open No. 2009-67691
- the use of arbutin-nano-dispersed particles is difficult to manufacture, and the product is not used, and there is a problem that it is not easily absorbed by the skin.
- dipeptides having a whitening effect are disclosed in Japanese Laid-Open Patent Publication No. Hei 5-032533, No. Hei. No. Hei.
- the amino acid side chains formed have thiol groups and derivatives thereof or aromatic groups or aromatic phenol groups and derivatives thereof, and the disclosed mechanism of the inhibition of melanin is not clear.
- the difference in inhibition rate of tyrosinase of dipeptides disclosed in Table 1 of Japanese Laid-Open Patent Publication No. 5-170637 can be from 3% to 56%, so that it is not limited to dipeptides.
- the compound can be a good whitening active ingredient.
- glycine acid which has a function of inhibiting melanin production and can be used as an active ingredient for skin whitening, and can be applied to each A whitening composition.
- one of the objects of the present invention is to provide a glycine derivative having a structure which does not have an aromatic group, an aromatic phenol and a biological group thereof, a sterol and a biological group thereof, and which has no optical activity, and is one.
- a derivative structure having oxidative stability and a single physiological activity. It also has good color stability in the formulation.
- R 1 represents an alkyl group of C1 C4
- R 2 represents a hydrogen atom or a fluorenyl group
- n represents an integer of 1 to 6.
- the glycine derivative is 3 (2-acetylamino-acetylamino)-propionic acid or
- the glycine derivative is 4-(2-acetetylamino-acetylamino)-butyric acid or Acetyl-Glycine- ⁇ -aminobutyric Acid), having the structure of formula (III) shown below:
- the glycine derivative is [( 2 -acetamido-acetyl)-mercapto-amino]acetic acid ([(2-Acetylamino-acetyl)-methyl-ami no]-acetic acid Or Acetyl-Glycine- Sarcosine), having the structure of formula (IV) shown below: . (IV)
- an aqueous solution of 0.05 to 10% by weight of a glycine derivative and a buffer solution thereof are added, and the light transmittance in the wavelength range of 420 to 500 nm is 97% or more.
- the above buffer solution is formed by citric acid and its salts.
- the above aqueous solution containing 0.05 to 10% by weight of a glycine derivative and a buffer solution thereof have a light transmittance of 98% or more at a specific wavelength of 440 nm.
- a whitening composition which is formed by adding 0.05 wt% to 10 wt% (by weight) of the above glycine f; anthraquinone, and has a function of inhibiting melanin production. More preferably, the above whitening composition is formed by adding 0.5 wt% to 2 wt% (by weight) of the above glycine derivative.
- the mechanism for inhibiting melanin production is not known, the real face is confirmed to have a function of inhibiting melanin production. Moreover, because of its structure, it does not have aromatic groups, aromatic phenols and their guanidine bio-groups, thiols and their "staining bio-groups", which is an oxidatively stable ruthenium biological structure, which is difficult to manufacture and store in whitening formulations. Oxidative deterioration, color stability, no obvious cytotoxicity, harmless to the human body, and convenient for the manufacture, application and storage of whitening compositions, can improve the stability of the formulation.
- the glycine derivatives of the present invention are not It has no enantiomer, which means that the glycine derivative of the present invention does not cause physiological activity differences due to impurities of other optical isomers, and all added components are active ingredients.
- the glycine derivative of the present invention is particularly suitable for use in the formulation of a water-based cosmetic care product having a transparent appearance.
- the present invention relates to a compound which is an active ingredient for whitening. According to the study by the present inventors, it has been found that the whitening effect of the dipeptide is quite different, although various dipeptides having a whitening effect have been disclosed in the literature (for example, Japanese Laid-Open Patent Publication No. 5-032533, No. In the case of the dipeptide, which is composed of one amino acid and contains one peptide bond, the present inventors have found that the inhibition of the dipeptide is found in the case of the second peptide.
- the functions of carbonylation, saccharification, oxidation, etc. vary depending on their structure, and in particular, inhibition of tyrosinase activity or inhibition of polyphenol oxidase activity cannot be determined solely by the peptide bond, that is, The structure of the dipeptide, that is, the properties of the two amino acids constituting the dipeptide, cannot be judged simply by the fact that the dipeptide has a function of inhibiting melanin production. For example, carnos ine is known to act as an antioxidant, but does not have the effect of inhibiting melanin production.
- ⁇ Inhibit ion of polyphenol oxidases act ivi ty by var ious dipept ides, A. Girel li, E. Mattei, A. Mess ina, and A. Tarola, J. of Agricul tural and Food Chemis try, 2004, 52. 2741-2745), which discloses the inhibition of the activity of various dipeptides on the oxidase activity, and found that not all dipeptides to polyphenol oxidase The activity has an inhibitory effect. Further, for example, in Japanese Patent Laid-Open No.
- the difference in the inhibition rate of the tyrosine alcohol disclosed by the two peptides disclosed in Table 1 can be from 3% to 56%.
- the inhibition of tyrosinase by the dipeptide is not determined by the peptide bond, but actually depends on the structure of the dipeptide compound.
- R 1 represents an alkyl group of CI to C4
- R 2 represents a hydrogen atom or a methyl group
- n represents an integer of from 1 to 6.
- the glycine derivative is 3 (2-acety lamino-acetylamino)-propionic acid or Acetyl-Glycine- ⁇ -Alanine , having the structure of the chemical formula (II) shown below:
- the glycine derivative is 4-(2-Acetylamino-acetylamino)-butyric acid. or Acetyl-Glycine-Y- Aminobutyr ic acid ), having the structure of the chemical formula (III) shown below:
- the glycine derivative is [(2-acetamido-acetyl)-methyl-amino]acetic acid ([(2-Acetylamino-acetyl)-methyl-amino]-acetic acid) Or Acetyl-Glycine- Sarcos ine), having the structure of formula (IV) shown below:
- an aqueous solution of the glycine derivative of the present invention and a buffer solution thereof in an amount of from 0.05 to 10% by weight (by weight) are added, and the light transmittance in the wavelength range of 420 500 nm is 97% or more.
- the aqueous solution and the buffer solution to which the above-mentioned glycine acid derivative is added in an amount of 0.05 to 10% by weight, and the light transmittance is 98% or more at a specific wavelength of 440 nm.
- a whitening composition which is prepared by adding a 0.05% by weight to 10% by weight (by weight) of the glycine derivative according to the present invention, and has an inhibitory effect on melanin production.
- the above whitening composition is more preferably added by adding a glycine derivative of the present invention in an amount of from 0.1% by weight to 2% by weight.
- the glycine derivative according to the present invention is known to have an effect of inhibiting melanin production via cell solid H.
- the glycine derivative of the present invention When applied to the skin, the glycine derivative of the present invention has a low molecular weight property and is easily absorbed by the skin, and the glycine derivative of the present invention does not have an optical entropy (no enant iomer), which means that the present invention Glycine f organisms do not differ in physiological activity due to impurities in other optical isomers, and all added components are active ingredients.
- acetylglycine (a; Ac-Gly-OH; 3. 77 g, 32. 2 mmol) and triethylamine (triethylamine; 6.7 ml; 48.1 mol) were dissolved in 160 ml of tetrahydrofuran ( In THF), after cooling to -10 ° C, isobutyl chloroformate (i sobutylchloroformate; 5. 02 g, 38.6 mmol). The mixed solution was stirred at -1 (TC) for 1 hour. Further, ⁇ -alanine benzyl ester p-methylate (e; ⁇ - ⁇ -Ala-OBzl. PTSA; 11.26 g, 32.
- Acetylglycine (a; Ac-Gly-OH; 2.52 g, 21.6 mmol) and triethylamine (triethylamine; 5.0 ml; 36.1 mmol) were dissolved in 100 mL of tetrahydrofuran (THF), cooled After -10 ° C, isobutylchloroformate (3.2 g, 23.8 mmol) was added. The mixed solution was stirred at -10 ° C for 1 hour. Further, benzyl p-Y-butylamine was added to toluene ⁇ "Acetate (e; H- Y Abu-OBzI.
- PTSA 7.6 g, 20.8 mmol
- triethylamine triethylamine
- THF tetrahydrofuran
- the obtained compound (hereinafter referred to simply as the compound (III)) was analyzed by a hydrogen-nuclear magnetic resonance spectrometer, and the obtained spectrum was obtained (1.58-1.64, in, 2H; 1.85, s, 3H; 2.19-2.22, t, 2H).
- Acetylglycine (a; Ac-Gly-OH; 4.10 g, 35.0 mmol), benzyl phenyl ester p-toluenesulfonate; Sar-OBzl.
- PTSA lL71g, 33.3 mmol, triethylamine (5.58 ml; 40.0 mmol), N-hydroxybenzotriazole (HOBt; 1.35 g, 10.0 mmol) and N,N,-dicyclohexyl Carbonimide (N, N, -dicyclohexyl carbodimide; DCC; 8.25 g, 40.0 mmol) was stirred and stirred in 200 ml of tetrahydrofuran (THF) overnight.
- THF tetrahydrofuran
- the mixed solution was filtered to remove dicyclohexylurea (DOT), and THF was removed by vacuum drying.
- DOT dicyclohexylurea
- the residue was dissolved in 100 ml of ethyl acetate, washed twice with 100 ml of a 10% aqueous solution of citric acid, washed twice with 100 ml of a 5% aqueous solution of sodium bicarbonate, and washed with 100 ml of brine.
- the obtained compound (hereinafter referred to as the compound (IV)) was analyzed by a hydrogen-nuclear magnetic resonance spectrometer, and the H-ray R spectrum was obtained, and the peak value was as follows. Shown: (Major: 1.86, s, 3H; 2.99, s, 3H; 3.96, d, 2H; 3.99, s, 2H; 7.94, s, 1H; 12.6-12.9, m, 1H.
- the cytotoxicity was evaluated by the MTT Assay method. All the compounds tested for whitening efficacy had a LD50 of more than 5000 fflg/kg for 3T3 fibroblasts and B16-F1G cells, and the compounds (11), (III) and (IV) is safe to use as a known and safe to use vitamin C derivative, a compound that is not cytotoxic and harmless to humans.
- Mouse melanoma metastasis cells (Mus musculus skin melanoma; B16-F10) were injected into a 96-well plate (960-well plate) to make 5000 cells per cell (5000 cells/well). 7 Culture at 37 °C. broth in 5% C0 2 and 10% FBS (Fetal Bovine Serum Dulbecco 'smodif ied Eagle' s medium; FBS DMEM).
- FBS Fetal Bovine Serum Dulbecco 'smodif ied Eagle' s medium
- melanin production rate (%) 100%
- 0 is the absorbance value of the test sample solution measured by spectrophotometry at a wavelength of 405 nm, that is, the OD (optical density) value, that is, the absorbance value when the compound (II), (III) or (IV) is used, and 0D B represents the wavelength.
- the absorbance of the blank control group at 405 nm, 0D N represents the absorbance of the negative control group at a wavelength of 405 nm. Lmg/ml ⁇ The control group (negative control; negative control group) containing 0.
- test sample solution first store 5wt% of compound (II), (III) or (IV) in phenol red free cultivating solution (phenol red free surface EM), ready to contain 0 Lmg/ml tyrosine (tyros ine) and ⁇ melanotropin 5wt% FBS medium (5wt% FBS DMEM), filtered with a 0.22 ⁇ m filter (because 0. lmg / ml tyrosine will cause The culture solution is supersaturated, so centrifugal filtration is required, and a test sample is prepared in the culture solution to obtain a test sample solution.
- test sample solution or reference sample (blank control group and background control group) to each well.
- 100 L of 1N sodium hydroxide (NaOH) After shaking for 10 minutes, the absorbance (0D value) at a wavelength of 405 nm was measured.
- the positive control group was Kojic acid (concentration: 500 ppm) and analyzed by statistical method (Student's t-test): according to the P value of less than 0.05.
- the test results are shown in Table 1.
- ascorbic acid glucoside represents ascorbic acid 2-glucoside (or AA2G)
- ethyl ascorbic acid is ethyl ascorbic acid
- ascorbic acid 2-alkali magnesium is represented ascorbic acid 2—phosphate magnesium
- the samples to be tested (compounds ( ⁇ ), (III) and (IV)) and the reference sample were respectively dissolved in water and a buffer having an H value of 6, to become a solution containing 0.5 wt% of the sample.
- a buffer solution having a pH of 6 used a mixed solution of 3.8 liters of 0.1 M citric acid and 16.2 liters of citrate.
- a 25 mg sample was dissolved therein to prepare a solution containing 0.5 wt% of the sample.
- the first embodiment of the formulation is as follows.
- PVM/MA Polyethylene decyl ether / maleic acid if
- Hyaluronic acid ⁇ Sodium Hyaluronate
- Glycerin Glycerin
- Methylisoxyl ketone Methyl isothiazol inone
- Polysorbate 20 can be mixed in a conventional manner. For example, the components in A are uniformly mixed, and then the components in B are separately added. After stirring, the premixed C is added. The ingredients in the mixture are added to the mixture of A and B, and stirred well.
- Formulation Example 2 is an example of the following whitening 4 Qinghualu. Whitening Essence
- Chrysanthemum extract Chamomilla Recutita (Matricaria) Flower Extract can be mixed by using conventional methods. For example, the components in A are uniformly mixed, and then the components in B are added separately. After stirring, it will already be The components in the mixture (prepared in D) are added to the mixture of A and B, and stirred uniformly.
- Formulation Example 3 is an example of the following 5 skin rejuvenation lotions.
- Glyceryl stearate Glyceryl Stearate
- PEG-75 stearate PEG- 75 Stearate
- Stearyl ether - 20 Steareth-20
- Macadamia oil Macadamia Integr ifol ia Nut Oi l mixing method, you can use the existing methods, such as heating the components in A and B to 8 (TC, stirring, and then B composition A mixture of the components was added to a mixture of the components of A, stirred for 5 minutes, then cooled, neutralized by adding sodium hydroxide, and the temperature was lowered to 45 ° C, and the components in C were added one by one, and the mixture was uniformly stirred.
- the glycine derivative according to the present invention can be used as an active ingredient for inhibiting melanin production, and can be incorporated into various skin care products and cosmetics, and can be, for example, creams, lotions, gels, lotions, and the like.
- active ingredients of whitening Various types, as active ingredients of whitening, their efficacy experiments have confirmed the function of inhibiting melanin production, and because of its structure does not have aromatic groups, aromatic phenols and their derivative groups, thiols and their derivative groups, It is a derivative structure with oxidation stability. It is not easy to oxidize and deteriorate during the application and storage of whitening formula. It has color and odor stability, and has no obvious cytotoxicity. It is harmless to human body. Further, the glycine derivative of the present invention does not have optical activity (no
- the glycine derivative of the present invention does not cause physiological activity differences due to impurities of other optical isomers, and all added components are active ingredients.
- the glycine derivatives of the present invention have good stability, and are especially applied to a water-based cosmetic care product formulation having a transparent appearance.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Dermatology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Cosmetics (AREA)
- Peptides Or Proteins (AREA)
Description
Claims
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13/128,446 US20130195782A1 (en) | 2010-10-22 | 2010-10-22 | Novel Glycine Derivative Capable Of Inhibiting Melanin Formation And Composition Using The Same |
PCT/CN2010/001665 WO2012051741A1 (zh) | 2010-10-22 | 2010-10-22 | 抑制黑色素生成的甘胺酸衍生物及其美白组合物 |
CN201080002871.7A CN103298778B (zh) | 2010-10-22 | 2010-10-22 | 具有抑制黑色素生成的甘胺酸衍生物及使用其的美白组成物 |
ES10858529.0T ES2670618T3 (es) | 2010-10-22 | 2010-10-22 | Derivados de glicina que inhiben la producción de melanina y composición de blanqueamiento de los mismos |
KR1020127020368A KR101414942B1 (ko) | 2010-10-22 | 2010-10-22 | 멜라닌 생성을 억제하는 글리신 유도체 및 그 미백 조성물 |
JP2012555272A JP5599905B2 (ja) | 2010-10-22 | 2010-10-22 | メラニン生成を抑制するグリシン誘導体及び美白組成物 |
EP10858529.0A EP2641894B1 (en) | 2010-10-22 | 2010-10-22 | Glycin derivatives inhibiting melanin production and whitening composition thereof |
US14/159,741 US8927499B2 (en) | 2010-10-22 | 2014-01-21 | Glycine derivative capable of inhibiting melanin formation and composition using the same |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/CN2010/001665 WO2012051741A1 (zh) | 2010-10-22 | 2010-10-22 | 抑制黑色素生成的甘胺酸衍生物及其美白组合物 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/128,446 A-371-Of-International US20130195782A1 (en) | 2010-10-22 | 2010-10-22 | Novel Glycine Derivative Capable Of Inhibiting Melanin Formation And Composition Using The Same |
US14/159,741 Continuation US8927499B2 (en) | 2010-10-22 | 2014-01-21 | Glycine derivative capable of inhibiting melanin formation and composition using the same |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2012051741A1 true WO2012051741A1 (zh) | 2012-04-26 |
Family
ID=45974610
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2010/001665 WO2012051741A1 (zh) | 2010-10-22 | 2010-10-22 | 抑制黑色素生成的甘胺酸衍生物及其美白组合物 |
Country Status (7)
Country | Link |
---|---|
US (2) | US20130195782A1 (zh) |
EP (1) | EP2641894B1 (zh) |
JP (1) | JP5599905B2 (zh) |
KR (1) | KR101414942B1 (zh) |
CN (1) | CN103298778B (zh) |
ES (1) | ES2670618T3 (zh) |
WO (1) | WO2012051741A1 (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104107146A (zh) * | 2013-04-18 | 2014-10-22 | 新钰生技股份有限公司 | 以甘胺酸衍生物抑制发炎与减少黑素亲和素表现的方法及其组合物 |
CN105503645A (zh) * | 2014-09-22 | 2016-04-20 | 新钰生技股份有限公司 | 一种化合物3(2-乙酰胺基-乙酰胺基)-丙酸的晶型a及其制备方法和应用 |
CN106397256A (zh) * | 2015-07-27 | 2017-02-15 | 新钰生技股份有限公司 | 一种用于抑制黑色素生成的化合物3(2-乙酰胺基-乙酰胺基)-丙酸的合成方法 |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8927767B2 (en) * | 2013-05-08 | 2015-01-06 | Corum Inc. | Crystalline polymorphs of acetyl-glycine-beta-alanine and process of making the same |
CN112717118B (zh) * | 2019-10-29 | 2023-03-31 | 中国食品发酵工业研究院有限公司 | 一种具有美白功能的大米肽及其制备方法 |
Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0532533A (ja) | 1991-07-25 | 1993-02-09 | Kyowa Hakko Kogyo Co Ltd | 化粧料 |
JPH05170637A (ja) | 1991-12-25 | 1993-07-09 | Narisu Keshohin:Kk | 美白化粧料 |
JPH06345797A (ja) | 1993-06-11 | 1994-12-20 | Yakult Honsha Co Ltd | ジペプチド及びこれを含有する化粧料 |
JPH0761905A (ja) | 1993-08-26 | 1995-03-07 | Mikimoto Pharmaceut Co Ltd | 美白化粧料 |
JPH07233022A (ja) | 1994-02-21 | 1995-09-05 | Shiseido Co Ltd | 皮膚外用剤 |
US6020367A (en) | 1997-12-02 | 2000-02-01 | Avon Products, Inc. | Supersaturated ascorbic acid solutions |
US6306376B1 (en) | 1997-07-08 | 2001-10-23 | L'oreal | Use of arbutin monoesters as depigmenting agents |
US6365135B1 (en) | 1997-12-19 | 2002-04-02 | L'oreal | Use of amino phenol amide derivatives as depigmentation agents |
US6801050B2 (en) | 2001-05-21 | 2004-10-05 | Hitachi, Ltd. | Driver circuit integrated with load current output circuit, pin electronics and IC tester having thereof |
JP2009067691A (ja) | 2007-09-11 | 2009-04-02 | Asuka Corporation:Kk | ナノ化アルブチンを含む美白化粧料 |
CN101654473A (zh) * | 2009-08-13 | 2010-02-24 | 上海力智生化科技有限公司 | 一种氨基保护甘氨酸二肽衍生物的合成方法 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2217196C2 (ru) * | 2002-02-28 | 2003-11-27 | Небольсин Владимир Евгеньевич | Способ индукции дифференцировки клеток |
-
2010
- 2010-10-22 JP JP2012555272A patent/JP5599905B2/ja active Active
- 2010-10-22 WO PCT/CN2010/001665 patent/WO2012051741A1/zh active Application Filing
- 2010-10-22 CN CN201080002871.7A patent/CN103298778B/zh active Active
- 2010-10-22 ES ES10858529.0T patent/ES2670618T3/es active Active
- 2010-10-22 KR KR1020127020368A patent/KR101414942B1/ko active IP Right Grant
- 2010-10-22 EP EP10858529.0A patent/EP2641894B1/en active Active
- 2010-10-22 US US13/128,446 patent/US20130195782A1/en not_active Abandoned
-
2014
- 2014-01-21 US US14/159,741 patent/US8927499B2/en active Active
Patent Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0532533A (ja) | 1991-07-25 | 1993-02-09 | Kyowa Hakko Kogyo Co Ltd | 化粧料 |
JPH05170637A (ja) | 1991-12-25 | 1993-07-09 | Narisu Keshohin:Kk | 美白化粧料 |
JPH06345797A (ja) | 1993-06-11 | 1994-12-20 | Yakult Honsha Co Ltd | ジペプチド及びこれを含有する化粧料 |
JPH0761905A (ja) | 1993-08-26 | 1995-03-07 | Mikimoto Pharmaceut Co Ltd | 美白化粧料 |
JPH07233022A (ja) | 1994-02-21 | 1995-09-05 | Shiseido Co Ltd | 皮膚外用剤 |
US6306376B1 (en) | 1997-07-08 | 2001-10-23 | L'oreal | Use of arbutin monoesters as depigmenting agents |
US6020367A (en) | 1997-12-02 | 2000-02-01 | Avon Products, Inc. | Supersaturated ascorbic acid solutions |
US6365135B1 (en) | 1997-12-19 | 2002-04-02 | L'oreal | Use of amino phenol amide derivatives as depigmentation agents |
US6801050B2 (en) | 2001-05-21 | 2004-10-05 | Hitachi, Ltd. | Driver circuit integrated with load current output circuit, pin electronics and IC tester having thereof |
JP2009067691A (ja) | 2007-09-11 | 2009-04-02 | Asuka Corporation:Kk | ナノ化アルブチンを含む美白化粧料 |
CN101654473A (zh) * | 2009-08-13 | 2010-02-24 | 上海力智生化科技有限公司 | 一种氨基保护甘氨酸二肽衍生物的合成方法 |
Non-Patent Citations (4)
Title |
---|
A. GIRELLI; E. MATTEI; A. MESSINA; A. TAROLA: "Inhibition of polyphenol oxidases activity", J. OF AGRICULTURAL AND FOOD CHEMISTRY, vol. 52, 2004, pages 2741 - 2745, XP008161146, DOI: doi:10.1021/jf0305276 |
DERMATITIS, vol. 42, no. L, January 1995 (1995-01-01), pages 9 - 13 |
GIRELLI ANNA M. ET AL.: "Inhibition of Polyphenol Oxidases Activity by Various Dipeptides", JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, vol. 52, no. 10, 2004, pages 2741 - 2745, XP008161146 * |
LI TONG: "Ingredients in skin lightening", DETERGENT COSMETICS, vol. 32, no. 7, July 2009 (2009-07-01), pages 43 - 45, XP008161260 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104107146A (zh) * | 2013-04-18 | 2014-10-22 | 新钰生技股份有限公司 | 以甘胺酸衍生物抑制发炎与减少黑素亲和素表现的方法及其组合物 |
CN105503645A (zh) * | 2014-09-22 | 2016-04-20 | 新钰生技股份有限公司 | 一种化合物3(2-乙酰胺基-乙酰胺基)-丙酸的晶型a及其制备方法和应用 |
CN105503645B (zh) * | 2014-09-22 | 2017-10-24 | 新钰生技股份有限公司 | 一种化合物3(2‑乙酰胺基‑乙酰胺基)‑丙酸的晶型a及其制备方法和应用 |
CN106397256A (zh) * | 2015-07-27 | 2017-02-15 | 新钰生技股份有限公司 | 一种用于抑制黑色素生成的化合物3(2-乙酰胺基-乙酰胺基)-丙酸的合成方法 |
Also Published As
Publication number | Publication date |
---|---|
KR20120130093A (ko) | 2012-11-28 |
EP2641894A1 (en) | 2013-09-25 |
ES2670618T3 (es) | 2018-05-31 |
US8927499B2 (en) | 2015-01-06 |
KR101414942B1 (ko) | 2014-07-04 |
JP2013521236A (ja) | 2013-06-10 |
EP2641894A4 (en) | 2016-04-20 |
US20140134121A1 (en) | 2014-05-15 |
US20130195782A1 (en) | 2013-08-01 |
CN103298778A (zh) | 2013-09-11 |
JP5599905B2 (ja) | 2014-10-01 |
EP2641894B1 (en) | 2017-12-27 |
CN103298778B (zh) | 2015-03-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2000510490A (ja) | 脱色剤としてのアミノフェノールアミド誘導体の使用 | |
KR100287242B1 (ko) | 탈색제로서의옥사메이트유도체의용도 | |
WO2012051741A1 (zh) | 抑制黑色素生成的甘胺酸衍生物及其美白组合物 | |
KR101735996B1 (ko) | 레스베라트릴 트리글리콜레이트를 포함하는 피부미백용 화장료 조성물 | |
KR19990082869A (ko) | 아미노산 유도체 및 염증인자 활성화 억제제 | |
ES2412061T3 (es) | Composición cosmética que comprende un derivado de leucodopacroma | |
JP5138262B2 (ja) | 皮膚外用剤 | |
KR102414390B1 (ko) | 꽃차 추출물을 함유하는 항산화, 미백 및 주름 개선을 위한 조성물 | |
KR101462692B1 (ko) | 피부미백용조성물 | |
JP4956164B2 (ja) | メラニン輸送及び/又は放出抑制剤 | |
JP5552741B2 (ja) | 亜鉛を有効成分として含有する美白剤 | |
TWI418366B (zh) | 具有抑制黑色素生成之甘胺酸衍生物及使用其之美白組成物 | |
KR20170122671A (ko) | 미백개선과 주름개선 효과를 갖는 배 캘러스와 유자 캘러스 소재 | |
AU2003200465B2 (en) | Compositions for Skin Lightening and Toning Down Pigment Disorders, Comprising Creatinine and/or Creatinine Derivatives as Active Substances | |
KR20100061978A (ko) | 피부미백용조성물 | |
KR20040040792A (ko) | 아미노산 또는 펩타이드가 결합된 레티놀 유도체 및 이를포함하는 피부노화 방지용 화장료 조성물 | |
KR20000075870A (ko) | 피부 및 표면 신체 생장물의 라이트닝을 위한, 페놀 유도체 및 붓꽃과 식물계의 추출물의 조합물, 및 그것을 함유하는 조성물 | |
JP5473343B2 (ja) | セロトニン化合物、チロシナーゼ阻害剤及び美白化粧料 | |
CN104257515B (zh) | 具有抑制黑色素生成的甘胺酸衍生物及使用其的美白组成物 | |
JP4047230B2 (ja) | 皮膚外用剤 | |
JP4959104B2 (ja) | 美白剤及び皮膚外用剤 | |
JP4959103B2 (ja) | 美白剤及び皮膚外用剤 | |
JP5600421B2 (ja) | 皮膚外用剤 | |
KR20230073422A (ko) | 타이로시나제 저해 활성을 갖는 화합물을 포함하는 피부 미백용 조성물 | |
JPH0640896A (ja) | メラニン生成抑制剤及びこれを含有する化粧料 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 13128446 Country of ref document: US |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 10858529 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010858529 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1864/MUMNP/2012 Country of ref document: IN |
|
ENP | Entry into the national phase |
Ref document number: 20127020368 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2012555272 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |